Press Releases

Date Title and Summary Additional Formats
Toggle Summary Marinus Pharmaceuticals Announces Pricing of Public Offering of Common Stock
RADNOR, Pa. , Dec. 12, 2018 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) (“Marinus” or the “Company”) announced the pricing of an underwritten public offering of 12,000,000 shares of common stock at a public offering price of $3.75 per share....
View HTML
Toggle Summary Marinus Pharmaceuticals Announces Public Offering of Common Stock
RADNOR, Pa. , Dec. 11, 2018 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS), (“Marinus” or the “Company”) today announced that it intends to offer and sell 12,000,000 shares of its common stock in an underwritten public offering.  All of the shares in the offering are to be sold by...
View HTML
Toggle Summary Marinus Pharmaceuticals Announces Positive Ganaxolone Data in Women With Postpartum Depression
Ganaxolone was safe and well-tolerated Ganaxolone IV demonstrated fast-acting, robust and durable efficacy Interim data with ganaxolone oral supports IV to oral administration Conference call to be held today at 8:30 AM ET RADNOR, Pa. , Dec. 10, 2018 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals,...
View HTML
Toggle Summary Marinus Pharmaceuticals Phase 2 Clinical Trial Data Show Long-term Effectiveness of Ganaxolone in Reducing Seizure Frequency in CDKL5 Deficiency Disorder Patients
Predictive biomarker also identified in PCDH19-related pediatric epilepsy RADNOR, Pa. , Dec. 04, 2018 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and...
View HTML
Toggle Summary Marinus Pharmaceuticals to Present Ganaxolone Clinical Trial Data in CDKL5 Deficiency Disorder and PCDH19-Related Epilepsy at AES
RADNOR, Pa. , Nov. 19, 2018 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that two abstracts...
View HTML
Toggle Summary Marinus Pharmaceuticals Provides Business Update and Third Quarter 2018 Financial Results
RADNOR, Pa. , Oct. 29, 2018 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (“Marinus” or “Company”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today provided a business update on its...
View HTML
Toggle Summary Marinus Pharmaceuticals Names Dr. Rolando Gutíerrez-Esteinou as VP of Clinical Development and Pharmacovigilance
RADNOR, Pa. , Oct. 10, 2018 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, announced the appointment of Rolando Gutíerrez-Esteinou, M.D., as Vice...
View HTML
Toggle Summary Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)
RADNOR, Pa. , Oct. 09, 2018 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that the Compensation...
View HTML
Toggle Summary Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
RADNOR, Pa. , Oct. 05, 2018 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc.  (Nasdaq:MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that the Compensation...
View HTML
Toggle Summary Marinus Completes Enrollment in its Magnolia Postpartum Depression Study
RADNOR, Pa. , Sept. 25, 2018 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, announced it has recently completed enrollment in its Magnolia Study –...
View HTML